Stay updated on Safety and Tolerability of Nivolumab and Cabiralizumab Clinical Trial
Sign up to get notified when there's something new on the Safety and Tolerability of Nivolumab and Cabiralizumab Clinical Trial page.

Latest updates to the Safety and Tolerability of Nivolumab and Cabiralizumab Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page shows a revision update from v3.3.1 to v3.3.2. No study content, eligibility criteria, outcomes, or other critical information was changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedThe page shows a minor site revision update: addition of Revision: v3.3.1 and removal of Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check29 days agoChange DetectedRemoved the government funding lapse notice; the page no longer displays an administrative banner about funding status, which does not impact the study details or how a user interacts with the page.SummaryDifference0.4%

- Check43 days agoChange DetectedThe page changes appear to be cosmetic UI/layout updates to the study record; core content such as the study title, conditions, eligibility criteria, and outcomes remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check72 days agoChange DetectedUpdate adds a government-funding status notice and NIH Clinical Center operating details with a v3.2.0 revision, while removing the old v3.1.0 tag.SummaryDifference5%

- Check79 days agoChange DetectedUpdated the page from revision v3.0.2 to v3.1.0, signaling a new release version.SummaryDifference0.1%

Stay in the know with updates to Safety and Tolerability of Nivolumab and Cabiralizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Tolerability of Nivolumab and Cabiralizumab Clinical Trial page.